Biosimilars Education | Biosimilars CME/CE Learning Center

Education

Biosimilars

Free online continuing education on Biosimilars! Get quality activities, articles, & videos to improve your Biosimilars education.

Results 1 - 29 of 29

Biosimilars: Applying the Science to Hematology/Oncology Practice

biosims-archmed icon23

Top Questions about Biosimilars in Dermatology

biosims-archmed icon1

Top Questions about Biosimilars in Gastroenterology

biosims-archmed icon2

Top Questions about Biosimilars in Rheumatology

biosims-archmed icon

Top Questions about Biosimilars in Hematology/Oncology

biosims-gastro2

Biosimilars and Patients with Inflammatory Bowel Disease

biosims-gastro1

Biosimilars: The New Era of Gastroenterology Management Considerations

Considering Biosimilars in Patients Failing their Initial Biologic

When to Switch? Biologically Experienced Patients with Spondyloarthritis

Innovator or Biosimilar for a Patient with Rheumatoid Arthritis

IL-gastro-case3

Ulcerative Colitis: What Can You Expect When a Patient is Switched to a Biosimilar?

IL-gastro-case2

Biosimilars in Patients with Crohn’s Disease Failing an Initial Biologic

IL-gastro-case1

Innovator or Biosimilar for a Patient with Ulcerative Colitis?

Switching Between Biologics: Is a Biosimilar an Option?

When to Switch? Biologically Experienced Psoriasis Patients

Innovator or Biosimilar for a Patient with Psoriasis

Interchangeability and Pharmacy-Level Substitution

FDA Criteria: Biosimilar Approval, Manufacturing, & Naming

What is the Difference Between a Biosimilar and a Generic?

What is a Biologic?

Sorting it Out: Biologics, Biosimilars, Small Molecule Drugs, and Generics

Are You Ready to Use Biosimilars in Your Practice?

Health Care Providers’ Perspectives on Biosimilars: Based in Fact or Not?

Pharmacovigilance and Biosimilars: Any Special Considerations?

Interchangeability and Biosimilars: What will this Mean for Clinical Practice?

Can a Biosimilar be Used for the Same Indications Approved for the Reference Biologic?

Biosimilars: As Safe and Effective as the Reference Product?

Drift and the Manufacturing of Biologics: What is it and Does it Matter?

Biosimilars in Clinical Practice: Interchangeability and Extrapolation